Wedbush Securities Inc. increased its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 9.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,875 shares of the medical research company’s stock after acquiring an additional 405 shares during the quarter. Wedbush Securities Inc.’s holdings in Edwards Lifesciences were worth $933,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of EW. Executive Wealth Management LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth $25,000. Sontag Advisory LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth $26,000. Lindbrook Capital LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth $27,000. Capital Financial Planning LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth $28,000. Finally, WP Advisors LLC purchased a new stake in Edwards Lifesciences in the first quarter worth $35,000. Institutional investors and hedge funds own 84.88% of the company’s stock.

NYSE:EW opened at $177.26 on Friday. The firm has a market cap of $36.88 billion, a P/E ratio of 37.71, a price-to-earnings-growth ratio of 2.46 and a beta of 0.91. Edwards Lifesciences Corp has a 52-week low of $123.00 and a 52-week high of $197.86. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.61 and a quick ratio of 1.92.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, January 31st. The medical research company reported $1.17 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.17. The company had revenue of $977.70 million during the quarter, compared to analyst estimates of $973.72 million. Edwards Lifesciences had a return on equity of 31.09% and a net margin of 19.40%. During the same quarter last year, the company earned $0.94 earnings per share. Equities research analysts anticipate that Edwards Lifesciences Corp will post 5.22 EPS for the current year.

In related news, VP Larry L. Wood sold 6,716 shares of Edwards Lifesciences stock in a transaction on Monday, February 4th. The stock was sold at an average price of $169.10, for a total transaction of $1,135,675.60. Following the completion of the sale, the vice president now owns 35,224 shares of the company’s stock, valued at $5,956,378.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock in a transaction dated Tuesday, February 12th. The stock was sold at an average price of $176.90, for a total value of $5,802,320.00. Following the sale, the chief executive officer now directly owns 75,926 shares of the company’s stock, valued at approximately $13,431,309.40. The disclosure for this sale can be found here. Insiders have sold 114,328 shares of company stock valued at $20,121,304 in the last three months. 1.63% of the stock is owned by corporate insiders.

A number of analysts have issued reports on EW shares. Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Monday, February 4th. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price target on shares of Edwards Lifesciences in a research report on Sunday, February 3rd. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $180.00 to $190.00 in a research report on Friday, January 18th. Canaccord Genuity reiterated a “buy” rating and issued a $215.00 price target (up from $190.00) on shares of Edwards Lifesciences in a research report on Monday, March 18th. Finally, Deutsche Bank began coverage on Edwards Lifesciences in a research report on Wednesday, January 2nd. They issued a “hold” rating and a $164.00 price target for the company. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $182.29.

TRADEMARK VIOLATION NOTICE: “Edwards Lifesciences Corp (EW) Position Increased by Wedbush Securities Inc.” was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2019/04/20/edwards-lifesciences-corp-ew-position-increased-by-wedbush-securities-inc.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Read More: How is net asset value different from market price?

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.